Description: Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Home Page: www.pfizer.com
66 Hudson Boulevard East
New York,
NY
10001-2192
United States
Phone:
212 733 2323
Officers
| Name | Title |
|---|---|
| Dr. Albert Bourla D.V.M., Ph.D. | Chairman & CEO |
| Mr. Frank A. D'Amelio | CFO & Exec. VP |
| Mr. David M. Denton | Chief Financial Officer & Exec. VP |
| Dr. Mikael Dolsten M.D., Ph.D. | Chief Scientific Officer and Pres of R&D |
| Ms. Angela Hwang | Chief Commercial Officer & Pres of Global Biopharmaceuticals Bus. |
| Ms. Jennifer B. Damico | Sr. VP, Controller & Principal Accounting Officer |
| Ms. Lidia L. Fonseca | Exec. VP and Chief Digital & Technology Officer |
| Ms. Francesca M. DeMartino | Chief Investor Relations Officer |
| Mr. Douglas M. Lankler | Exec. VP & Gen. Counsel |
| Mr. Rady A. Johnson | Exec. VP and Chief Compliance, Quality & Risk Officer |
Exchange: IL
Country: GB : United Kingdom of Great Britain and Northern Ireland
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 11.0254 |
|---|---|
| Trailing PE: | 6.7287 |
| Price-to-Book MRQ: | 1.5597 |
| Price-to-Sales TTM: | 1.9673 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 83000 |